PHC Holdings Corp. (6523) AI Stock Analysis

• Market Cap: €124.69B
• Dividend Yield: 4.27%
• Average Volume (3M): 166.32K
• Price to Earnings (P/E): 11.0
• Beta (1Y): 0.53
• Revenue Growth: 0.70%
• EPS Growth: N/A
• Country: JP
• Employees: 9,245
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Devices
• EPS (TTM): -18.55
• Shares Outstanding: 126,721,820
• 10 Day Avg. Volume: 158,290
• 30 Day Avg. Volume: 166,323
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €993.29
• Price Target Upside: 0.94% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 74 Outperform
• Price Target: ¥1,027.00 ▲(4.37% Upside)

PHC Holdings Corp. receives a solid score driven primarily by its strong financial performance and attractive valuation. The company's improved profitability and robust cash flow are positive indicators, though high leverage remains a risk to monitor. While technical analysis provides mixed signals, the stock's current valuation offers potential upside for investors.

PHC Holdings Corp. Business Overview & Revenue Model

Company Description

PHC Holdings Corporation (6523) is a diversified global healthcare company headquartered in Japan. The company operates in several sectors, including diagnostics, life sciences, and medical devices, providing innovative solutions and products to improve patient care and health outcomes. Its core products and services range from clinical testing devices and laboratory equipment to advanced medical imaging technologies and healthcare IT solutions.

How the Company Makes Money

PHC Holdings Corp. generates revenue through the sale of its wide array of healthcare products and services. Key revenue streams include the direct sale of medical devices and diagnostic equipment to hospitals, clinics, and laboratories, as well as providing maintenance, support, and training services associated with these products. The company also benefits from strategic partnerships and collaborations with other healthcare and technology firms, which enhance its product offerings and market reach. Additionally, PHC Holdings may engage in research and development activities, leading to the creation of innovative products that meet emerging healthcare needs, thereby contributing to its earnings. While specific financial details and partnerships are not disclosed in this context, the company's diversified portfolio and global presence are significant factors in its revenue generation.

PHC Holdings Corp. Financial Statement Overview

Summary

PHC Holdings Corp. shows a positive financial trajectory with improved profitability and cash flow generation. Enhanced margins and strong cash flow performance are key strengths, but high leverage and modest revenue growth indicate areas for improvement.

Income Statement

PHC Holdings Corp. has shown a strong recovery in profitability with a Gross Profit Margin of 45.96% and a significant improvement in Net Profit Margin to 2.90% in 2025 from a negative margin in previous years. Revenue growth was consistent, increasing by 2.17% from 2024 to 2025. The EBIT Margin improved significantly to 6.08%, indicating better control over operating expenses. Overall, the company has effectively turned its financial performance around, although the relatively modest revenue growth suggests room for further expansion.

Balance Sheet

The company's Debt-to-Equity Ratio is high at 1.80, indicating significant leverage which poses a risk if not managed well. However, the Return on Equity (ROE) improved to 7.40%, reflecting better profitability. The Equity Ratio stands at 26.60%, showing a stable equity base. While the balance sheet reflects improved profitability, the high leverage remains a concern that could affect financial stability.

Cash Flow

PHC Holdings Corp. has demonstrated strong cash flow management with a Free Cash Flow of ¥30.33 billion in 2025 and a Free Cash Flow Growth Rate of 13.72% from 2024, reflecting positive cash generation. The Operating Cash Flow to Net Income Ratio is robust at 4.00, showcasing efficient conversion of income to cash. The company's ability to generate cash flow is a key strength, supporting its operational stability and investment capacity.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	361.59B	353.90B	356.43B	340.45B	306.07B
Gross Profit	166.22B	157.97B	169.13B	165.24B	143.65B
EBITDA	52.33B	30.15B	58.43B	56.89B	62.29B
Net Income	10.48B	-12.89B	-3.22B	-8.46B	16.91B
Balance Sheet
Total Assets	532.48B	564.33B	561.57B	591.32B	569.02B
Cash, Cash Equivalents and Short-Term Investments	39.59B	51.82B	63.25B	97.63B	63.96B
Total Debt	255.26B	285.05B	292.62B	307.94B	321.55B
Total Liabilities	391.31B	425.16B	422.74B	455.26B	461.46B
Stockholders Equity	141.64B	139.51B	138.01B	135.37B	107.02B
Cash Flow
Free Cash Flow	30.33B	26.67B	9.86B	39.32B	35.70B
Operating Cash Flow	41.94B	41.30B	21.38B	51.05B	47.85B
Investing Cash Flow	-8.47B	-21.07B	-17.52B	-12.52B	-16.31B
Financing Cash Flow	-39.07B	-39.14B	-40.83B	-7.01B	-20.39B

PHC Holdings Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 984.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6523, the sentiment is Positive. The current price of 984 is above the 20-day moving average (MA) of 918.15, above the 50-day MA of 912.38, and above the 200-day MA of 961.81, indicating a bullish trend. The MACD of 10.96 indicates Negative momentum. The RSI at 67.02 is Neutral, neither overbought nor oversold. The STOCH value of 69.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6523.

PHC Holdings Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6823	78 Outperform	¥33.04B	10.82		2.43%	7.99%	28.81%
6678	74 Outperform	¥16.48B	15.81		3.52%	-8.07%	-38.21%
6523	74 Outperform	€124.69B	10.97	8.31%	4.27%	0.70%	―
6849	73 Outperform	¥286.39B	20.88		1.81%	4.43%	-1.39%
4549	63 Neutral	¥74.06B	33.75		2.29%	3.80%	6.68%
7600	56 Neutral	¥14.33B	10.23		2.76%	4.84%	-148.94%
Sector *	51 Neutral	kr6.00B	8.72	-28.70%	2.26%	51.25%	19.20%